Horizon Pharma (HZNP) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Horizon (HZNP) Isn't Valeant - PiperJaffray
March 1, 2016 8:37 AM ESTPiper Jaffray analyst, David Amsellem, thinks that Horizon Pharma (NASDAQ: HZNP) is being painted with the same brush as Valeant and with shares trading at a 7x PE, he sees substantial value. The analyst reduced his PT to $44 from $46 but reiterated his Overweight rating.
Horizon reported 4Q15 adjusted EPS of $0.63 on... More
Mizuho Securities Remains Bullish on Horizon Pharma (HZNP); Says Subpoena Appears Benign
March 1, 2016 7:01 AM ESTMizuho Securities maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $34.00 (from $36.00), following the company's 4Q earnings report. HZNP reported a strong revenues of $244.5M and EPS of $0.63 vs. consensus estimates of $240.8M and $0.61. Mgmt indicated the... More
Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Despite Sell-Off; Says Business is Sustainable
February 29, 2016 3:37 PM ESTPiper Jaffray maintained an Overweight rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $44.00 (from $46.00), following the company's 4Q earnings report. Horizon reported adjusted EPS of $0.63 on revenues of $245M, coming in ahead of Street estimates. Sales from the primary care business grew 10% sequentially in 4Q15 over 3Q15, with management citing... More
